Zusammenfassung
Nach der Markteinführung der so genannten ‚atypischen Neuroleptika’ sind eine Reihe
von Berichten über erhöhte Blutfettwerte bei Patienten, die mit diesen Medikamenten
behandelt wurden, veröffentlicht worden. In dieser Übersicht sollen die bisher in
der Literatur beschriebenen Berichte und Studien referiert werden. Nach den bisher
vorliegenden Daten ist eine Hyperlipidämie besonders bei Patienten, die mit Clozapin,
Olanzapin und auch Quetiapin behandelt wurden, beobachtet worden. Es sind insbesondere
starke Anstiege der Serumkonzentrationen der Triglyzeride berichtet worden. Die zugrunde
liegenden Pathomechanismen sind noch nicht hinreichend geklärt. Da eine Hyperlipidämie
ein wichtiger Aspekt des so genannten metabolischen Syndroms ist, das sehr häufig
zu schwer wiegenden Folgeerkrankungen, v. a. Herz-/Kreislauferkrankungen, führt, sollte
einer Hyperlipidämie als einer möglichen Nebenwirkung von Neuroleptika vermehrt Aufmerksamkeit
gewidmet werden.
Abstract
After the introduction of the so-called ‘atypical antipsychotics’ some reports concerning
hyperlipidemia observed in patients treated with these drugs have been published.
The studies and case reports available up to now were reviewed. The available data
show that hyperlipidemia particularly occurred in patients receiving clozapine, olanzapine
and also quetiapine. Predominately elevated serum levels of triglycerides have been
reported. The underlying pathomechanism still remains widely unclear. Since hyperlipidemia
is an important symptom of the so called ‘metabolic syndrome’ which is often associated
with severe complications like cardial and vascular diseases, more attention should
be paid to hyperlipidemia as a potential side effect of antipsychotics.
Literatur
- 1 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener
Patienten. 2. Aufl. Bremen: Uni-Med 2000
- 2
Henderson D C.
Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities.
J Clin Psychiatry.
2001;
62 Suppl 23
39-44
- 3
Kato M M, Goodnick P J.
Antipsychotic medication: Effects on regulation of glucose and lipids.
Expert Opin Pharmacother.
2001;
2
1571-1582
- 4
Mclntyre R S, McCann S M, Kennedy S H.
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
Can J Psychiatry.
2001;
46
273-281
- 5
Assmann G, Schulte H.
The importance of triglycerides: results from the Prospective Cardiovascular Munster
(PROCAM) Study.
Eur J Epidemiol.
1992;
8 Suppl 1
99-103
- 6
Cullen P.
Evidence that triglycerides are an independent coronary heart disease risk factor.
Am J Cardiol.
2000;
86
943-949
- 7
Miller M.
The epidemiology of triglyceride as a coronary artery disease risk factor.
Clin Cardiol.
1999;
22 (6 Suppl)
II1-6
- 8
Laaser U.
Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie.
Z Kardiol.
1994;
83 Suppl 6
163-167
- 9
Richter W O, Richter V, Rassoul F, Sonnichsen A C, Rotzsch W, Schwandt P.
Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern.
Fortschr Med.
1993;
111
214-218
- 10
Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U.
Bochumer Cholesterin und Blutdruckscreening-Studie 1990.
Fortschr Med.
1992;
110
387-392
- 11
Hershcopf R J, Elahi D, Andres R, Baldwin H L, Raizes G S, Schocken D D, Tobin J D.
Longitudinal changes in serum cholesterol in man: an epidemiologic search for an etiology.
J Chronic Dis.
1982;
35
101-114
- 12
McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G.
Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma
Insulin and triglyceride concentrations.
J Clin Endocrinol Metab.
2000;
85
3085-3088
- 13
Richter W O, Sonnichsen A C, Schwandt P.
Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol
Screening Project.
J Clin Epidemiol.
1995;
48
1307-1317
- 14
Ford E S, Giles W H, Dietz W H.
Prevalence of the metabolic syndrome among US adults: findings from the third National
Health and Nutrition Examination Survey.
JAMA.
2002;
287
356-359
- 15
Wetterling T.
Hyperlipidämie - Nebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)?.
Psychiat Prax.
2002;
29
438-440
- 16
Koro C E, Fedder D O, Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W.
An assessment of the independent effects of olanzapine and risperidone exposure on
the risk of hyperlipidemia in schizophrenic patients.
Arch Gen Psychiatry.
2002;
59
1021-1026
- 17
Clark M L, Johnson P C.
Amenorrhea and elevated serum cholesterol produced by tri-fluoro-methylated phenothiazine.
J Clin Endocrinol Metab.
1960;
20
641-646
- 18
Clark M L, Ray T S, Paredes A, Ragland R E, Costiloe J P, Smith C W, Wolf S.
Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels
and cholesterol-behavior relationships.
Psychosom Med.
1967;
29
634-642
- 19
Mefferd R B, Labrosse E H, Gawienowski A M.
Influence of Chlorpromazine on biochemical variables of male schizophrenics.
J Nerv Ment Dis.
1958;
127
167-179
- 20
Sasaki J, Funakoshi M, Arakawa K.
Lipids and apolipoproteins in patients treated with major tranquillizers.
Clin Pharmacol Ther.
1985;
37
684-687
- 21
Lund B C, Perry P J, Brooks J M, Arndt S.
Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia,
and hypertension: a claims-based approach.
Arch Gen Psychiatry.
2001;
58
1172-1176
- 22
Ghaeli P, Dufresne R L.
Serum triglyceride levels in patients treated with clozapine.
Am J Health Sys Pharm.
1996;
53
2079-2081
- 23
Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, Guy N, Gonen N, Weizman A.
Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and
serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients
maintained on clozapine.
Clin Neuropharmacol.
1998;
21
245-250
- 24
Gaulin B D, Markowitz J S, Caley C F, Nesbitt L A, Dufresne R L.
Clozapine-associated elevation in triglycerides.
Am J Psychiatry.
1999;
156
1270-1272
- 25
Wirshing D A.
Adverse effects of atypical antipsychotics.
J Clin Psychiatry.
2001;
62 Suppl 21
7-10
- 26
Braun G A, Paulois M E.
Sterol metabolism: biochemical differences among butyrophenons.
Int J Neuropsychiatry.
1967;
3 Suppl
26-27
- 27
Clark M L, Braun G A, Hewson J R, Serafetinides E A, Colmore J P, Rahhai D K.
Trifluoperidol and cholesterol in man.
Clin Pharmacol Ther.
1968;
9
333-340
- 28
Serafetinides E A, Colmore J P, Rahhai D K, Clark M L.
Trifluoperidol in chronic male psychiatric patients.
Behav Neuropsychiaty.
1971;
3
10-12
- 29
Simpson G M, Cooper T B.
The effect of three butyrophenones on serum cholesterol levels.
Curr Ther Res Clin Exp.
1966;
8
249-255
- 30
Simpson G M, Cooper T B, Braun G A.
Further studies on the effect of butyrophenons on cholesterol synthesis in humans.
Curr Ther Res Clin Exp.
1967;
9
413-418
- 31
Clark M, Dubowski K, Colmore J.
The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients.
Clin Pharmacol Ther.
1970;
11
883-889
- 32
Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K.
Decreased concentration of high density lipoprotein cholesterol in schizophrenics
treated with phenothiazines.
Atherosclerosis.
1984;
51
163-169
- 33
Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg l, Kotler M, Weizman A.
The impact on serum lipids of clozapine treatment in chronic schizophrenic patients.
Clin Neuropharmacol.
1999;
2
98-101
- 34
Meyer J M.
A rectrospective comparison of weight, lipid, and glucose changes between olanzapine-
and risperidone-treated inpatients: metabolic outcomes after 1 year.
J Clin Psychiatry.
2002;
63
425-433
- 35 Simpson G, Romano S J, Horne R L. et al .Ziprasidone versus olanzapine in schizophrenia:
Result of a double-blind study. New Orleans: American Psychiatric Association Annual
Meeting, NR 252 2001: 68-69 (zitiert nach 3)
- 36
Dursun S M, Szemis A, Andrews H, Reveley M A.
The effects of clozapine on levels of total cholesterol and related lipids in serum
of patients with schizophrenia: a prospective study.
J Psychiatry Neurosci.
1999;
24
453-455
- 37
Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C.
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic
study.
Am J Psychiatry.
2000;
157
975-981
- 38
Leonard P, Halley A, Browne S.
Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine.
Ir Med J.
2002;
95
119-120
- 39
Meyer J M.
Novel antipsychotics and severe hyperlipidemia.
J Clin Psychopharmacol.
2001;
21
369-374
- 40
Melkersson K l, Hulting A L, Brismar K E.
Elevated levels of Insulin, leptin, and blood lipids in olanzapine-treated patients
with schizophrenia or related psychoses.
J Clin Psychiatry.
2000;
61
742-749
- 41
Osser D N, Najarian D M, Dufresne R L.
Olanzapine increases weight and serum triglyceride levels.
J Clin Psychiatry.
1999;
60
767-770
- 42
Sheitman B B, Bird P M, Binz W, Akinli L, Sanchez C.
Olanzapine-induced elevation of plasma triglyceride levels.
Am J Psychiatry.
1999;
156
1471-1472
- 43
Kinon B J, Basson B R, Gilmore J A, Tollefson G D.
Long-term olanzapine treatment: weight change and weight-related health factors in
schizophrenia.
J Clin Psychiatry.
2001;
62
92-100
- 44
Daniel D G, Zimbroff D L, Potkin S G, Reeves K R, Harrigan E P, Lakshminarayanan M I.
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and
schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Neuropsychopharmacology.
1999;
20
491-505
- 45
Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan E P, Morrissey M R.
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective
disorder: a 4-week placebo-controlled trial.
Psychopharmacology.
1998;
140
173-184
- 46
Kingsbury S J, Fayek M, Trufasiu D, Zada J, Simpson G M.
The effects of Ziprasidone on cholesterol, triglycerides and glucose.
J Clin Psychiatry.
2001;
62
347-349
- 47 Romano S J, Cutler N, Weiden P J, Simpson G M. Ziprasidone's effects on weight
and lipids in patients with schizophrenia. Montreal: Poster, 23th Congress 23. - 27.
6. 2002
- 48
Wetterling T.
Gewichtszunahme - eine unterschätzte Nebenwirkung atypischer Neuroleptika?.
Fortschr Neurol Psychiat.
2000;
68
546-556
- 49
Brown C D, Higgins M, Donato K A, Rohde F C, Garrison R, Obarzanek E, Ernst N D, Horan M.
Body mass index and the prevalence of hypertension and dyslipidemia.
Obes Res.
2000;
8
605-619
- 50
Denke M A, Sempos C T, Grundy S M.
Excess body weight. An underrecognized contributor to high blood cholesterol levels
in white American men.
Arch Intern Med.
1993;
153
1093-1103
- 51
Denke M A, Sempos C T, Grundy S M.
Excess body weight. An underrecognized contributor to dyslipidemia in white American
women.
Arch Intern Med.
1994;
154
401-410
- 52
Thune l, Njolstad l, Lochen M L, Forde O H.
Physical activity improves the metabolic risk profiles in men and women: the Tromsö
Study.
Arch Intern Med.
1998;
158
1633-1640
- 53
Ferreira M F, Sobrinho L G, Santos M A, Sousa M F, Uvnas-Moberg K.
Rapid weight gain, at least in some women, is an expression of a neuroendocrine state
characterized by reduced hypothalamic dopaminergic tone.
Psychoneuroendocrinol.
1998;
23
1005-1013
- 54
Greenman Y, Tordjman K, Stern N.
Increased body weight associated with prolactin secreting pituitary adenomas: weight
loss with normalization of prolactin levels.
Clin Endocrinol.
1998;
48
547-553
- 55
Bapista T, Lacruz A, Mendoza S de, Mendoza Guilleri J M, Silvera A, Angeles F, Mendoza M T,
Hernandez L.
Body weight gain after administration of antipsychotic drugs: correlation with leptin,
insulin and reproductive hormones.
Pharmacopsychiatry.
2000;
33
81-88
- 56
Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J-C,
Hebebrand J.
Serum leptin levels increase rapidly after initiation of clozapine therapy.
Mol Psychiatry.
1998;
3
76-80
- 57
Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T.
Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka.
Fortschr Neurol Psychiat.
2001;
69
116-137
- 58
Kametani T, Koshida H, Nagaoka T, Miyakoshi H.
Hypertriglyceridemia is an independent risk factor for development of impaired fasting
glucose and diabetes mellitus: a 9-year longitudinal study in Japanese.
Intern Med.
2002;
41
516-521
- 59
McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G.
Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma
insulin and triglyceride concentrations.
J Clin Endocrinol Metab.
2000;
85
3085-3088
- 60 Wetterling T. Diabetes mellitus Typ II - induziert durch atypische Neuroleptika?. Fortschr
Neurol Psychiat 2003: 71 (in Druck)
Prof. Dr. Tilman Wetterling
Klinik für Psychiatrie und Psychotherapie - Gerontopsychiatrie · Vivantes Klinikum
Hellersdorf
Myslowitzer Str. 45
12621 Berlin
Email: t.wetterling@kh-hellersdorf.de
